Mechanism of Interleukin-1β induced-increase in mouse intestinal permeability in vivo

Journal of Interferon and Cytokine Research

Volumn 32, Issue 10, 2012, Pages 474-484

  Al Sadi, Rana ^a,b   Guo, Shuhong ^a,b   Dokladny, Karol ^a   Smith, Matthew A ^a   Ye, Dongmei ^a,b   Kaza, Archana ^a   Watterson, D Martin ^c,d   Ma, Thomas Y ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b VA Medical Center   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 IODO 1 NAPHTHALENESULFONYL)HEXAHYDRO 1H 1,4 DIAZEPINE; DEXTRAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; MYOSIN LIGHT CHAIN KINASE; RECOMBINANT INTERLEUKIN 1BETA; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; AZEPINES; CACO-2 CELLS; CROHN DISEASE; DEXTRANS; DISEASE MODELS, ANIMAL; ENTEROCYTES; HUMANS; INTERLEUKIN-1BETA; INTESTINES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOSIN-LIGHT-CHAIN KINASE; NAPHTHALENES; PERMEABILITY; RNA, SMALL INTERFERING; TIGHT JUNCTIONS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84867505323     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0031     Document Type: Article

References (117)

1. Akira S. 2000. The role of IL-18 in innate immunity. Curr Opin Immunol 12:59-63.
2. American Thoracic Society/European Respiratory Society. 2002. nternational multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277-304.
3. Arend WP, Palmer G, Gabay C. 2008. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223:20-38.
4. Arndt PG, Fantuzzi G, Abraham E. 2000. Expression of interleukin- 18 in the lung after endotoxemia or hemorrhageinduced acute lung injury. Am J Respir Cell Mol Biol 22:708-713.
5. Barnes PJ. 2008a. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8:183-192.
6. Barnes PJ. 2008b. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 118:3546-3556.
7. Barnes PJ, Shapiro SD, Pauwels RA. 2003. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur Respir J 22:672-688.
8. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. 1994. The American- European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818-824.
9. Brieland JK, Jackson C, Hurst S, Loebenberg D, Muchamuel T, Debets R, Kastelein R, Churakova T, Abrams J, Hare R, O'Garra A. 2000. Immunomodulatory role of endogenous interleukin-18 in gamma interferon-mediated resolution of replicative Legionella pneumophila lung infection. Infect Immun 68:6567-6573.
10. Case CL, Shin S, Roy CR. 2009. Asc and Ipaf Inflammasomes direct distinct pathways for caspase-1 activation in response to Legionella pneumophila. Infect Immun 77:1981-1991.
11. Cheung H, Chen NJ, Cao Z, Ono N, Ohashi PS, Yeh WC. 2005. ccessory protein-like is essential for IL-18-mediated signaling. J Immunol 174:5351-5357.
12. Dinarello C, Arend W, Sims J, Smith D, Blumberg H, O'Neill L, Goldbach-Mansky R, Pizarro T, Hoffman H, Bufler P, Nold M, Ghezzi P, Mantovani A, Garlanda C, Boraschi D, Rubartelli A, Netea M, van der Meer J, Joosten L, Mandrup-Poulsen T, Donath M, Lewis E, Pfeilschifter J, Martin M, Kracht M, Muehl H, Novick D, Lukic M, Conti B, Solinger A, Kelk P, van de Veerdonk F, Gabel C. 2010. IL-1 family nomenclature. Nat Immunol 11:973.
13. Dinarello CA. 2007. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 27:98-114.
14. Dinarello CA. 2011. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720-3732.
15. Elzinga BM, Twomey C, Powell JC, Harte F, McCarthy JV. 2009. Interleukin-1 receptor type 1 is a substrate for gamma-secretase- dependent regulated intramembrane proteolysis. J Biol Chem 284:1394-1409.
16. Franchi L. 2011. Role of inflammasomes in salmonella infection. Front Microbiol 2:8.
17. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, Wong W, Kamen R, Tracey D, Allen H. 1997. Caspase-1 processes IFN-gammainducing factor and regulates LPS-induced IFN-gamma production. Nature 386:619-623.
18. Harada M, Obara K, Hirota T, Yoshimoto T, Hitomi Y, Sakashita M, Doi S, Miyatake A, Fujita K, Enomoto T, Taniguchi M, Higashi N, Fukutomi Y, Nakanishi K, Nakamura Y, Tamari M. 2009. A functional polymorphism in IL-18 is associated with severity of bronchial asthma. Am J Respir Crit Care Med 180:1048-1055.
19. Hayakawa H, Hayakawa M, Kume A, Tominaga S. 2007. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 282:26369-26380.
20. Hoshino K, Tsutsui H, Kawai T, Takeda K, Nakanishi K, Takeda Y, Akira S. 1999. Cutting edge: Generation of IL-18 receptordeficient mice: Evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 162:5041-5044.
21. Hoshino T, Kato S, Oka N, Imaoka H, Kinoshita T, Takei S, Kitasato Y, Kawayama T, Imaizumi T, Yamada K, Young HA, Aizawa H. 2007. Pulmonary inflammation and emphysema: Role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med 176:49-62.
22. Hoshino T, Kawase Y, Okamoto M, Yokota K, Yoshino K, Yamamura K, Miyazaki J, Young HA, Oizumi K. 2001. Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol 166: 7014-7018.
23. Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H. 2009. Role of proinflammatory cytokines IL-18 and IL- 1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol 41:661-670.
24. Hoshino T, Wiltrout RH, Young HA. 1999. IL-18 is a potent coinducer of IL-13 in NK and T cells: A new potential role for IL-18 in modulating the immune response. J Immunol 162: 5070-5077.
25. Hoshino T, Yagita H, Ortaldo JR, Wiltrout RH, Young HA. 2000. n vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol 30:1998-2006.
26. Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, Lei HY. 2005. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol 75:185-194.
27. Imaoka H, Gauvreau GM, Watson RM, Smith SG, Dua B, Baatjes AJ, Howie K, Hoshino T, Killian KJ, Aizawa H, O'Byrne PM. 2011. Interleukin-18 and interleukin-18 receptor a expression in allergic asthma. Eur Respir J 38:981-983.
28. Imaoka H, Hoshino T, Takei S, Kinoshita T, Okamoto M, Kawayama T, Kato S, Iwasaki H, Watanabe K, Aizawa H. 2008. Interleukin-18 production and pulmonary function in COPD. Eur Respir J 31:287-297.
29. Izuhara K, Ohta S, Shiraishi H, Suzuki S, Taniguchi K, Toda S, Tanabe T, Yasuo M, Kubo K, Hoshino T, Aizawa H. 2009. The mechanism of mucus production in bronchial asthma. Curr Med Chem 16:2867-2875.
30. Kaarteenaho-Wiik R, Tani T, Sormunen R, Soini Y, Virtanen I, Paakko P. 1996 Tenascin immunoreactivity as a prognostic marker in usual interstitial pneumonia. Am J Respir Crit Care Med 154:511-518.
31. Kang MJ, Homer RJ, Gallo A, Lee CG, Crothers KA, Cho SJ, Rochester C, Cain H, Chupp G, Yoon HJ, Elias JA. 2007. IL-18 is induced and IL-18 receptor alpha plays a critical role in the pathogenesis of cigarette smoke-induced pulmonary emphysema and inflammation. J Immunol 178:1948-1959.
32. Kanneganti TD. 2010. Central roles of NLRs and inflammasomes in viral infection. Nat Rev Immunol 10:688-698.
33. Katzenstein AL, Myers JL. 1998. Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification. Am J Respir Crit Care Med 157:1301-1315.
34. Kawase Y, Hoshino T, Yokota K, Kuzuhara A, Kirii Y, Nishiwaki E, Maeda Y, Takeda J, Okamoto M, Kato S, Imaizumi T, Aizawa H, Yoshino K. 2003. Exacerbated and prolonged allergic and non-allergic inflammatory cutaneous reaction in mice with targeted interleukin-18 expression in the skin. J Invest Dermatol 121:502-509.
35. Kim DS, Collard HR, King TE, Jr. 2006. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 3:285-292.
36. Kinjo Y, Kawakami K, Uezu K, Yara S, Miyagi K, Koguchi Y, Hoshino T, Okamoto M, Kawase Y, Yokota K, Yoshino K, Takeda K, Akira S, Saito A. 2002. Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: A comparative study with IL-12p40. J Immunol 169:323-329.
37. Kitasato Y, Hoshino T, Okamoto M, Kato S, Koda Y, Nagata N, Kinoshita M, Koga H, Yoon DY, Asao H, Ohmoto H, Koga T, Rikimaru T, Aizawa H. 2004. Enhanced expression of interleukin- 18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 31:619-625.
38. Kuhn C, 3rd, Boldt J, King TE, Jr., Crouch E, Vartio T, McDonald JA. 1989. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 140:1693-1703.
39. Lauw FN, Branger J, Florquin S, Speelman P, van Deventer SJ, Akira S, van der Poll T. 2002. IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. J Immunol 168:372-378.
40. Levine SJ. 2004. Mechanisms of soluble cytokine receptor generation. J Immunol 173:5343-5348.
41. Martinon F, Burns K, Tschopp J. 2002. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417-426.
42. Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, Scalia MR, Akinbami LJ. 2007. National surveillance for asthma - United States, 1980-2004. MMWR Surveill Summ 56:1-54.
43. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. 2001. Interleukin- 18 regulates both th1 and th2 responses. Annu Rev Immunol 19:423-474.
44. Netea MG, Fantuzzi G, Kullberg BJ, Stuyt RJ, Pulido EJ, McIntyre RC, Jr., Joosten LA, Van der Meer JW, Dinarello CA. 2000. eutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J Immunol 164:2644-2649.
45. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. 2010. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11:1014-1022.
46. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. 1999. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity 10:127-136.
47. Okamoto M, Kato S, Oizumi K, Kinoshita M, Inoue Y, Hoshino K, Akira S, McKenzie AN, Young HA, Hoshino T. 2002. Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: A potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood 99:1289-1298.
48. Omoto Y, Tokime K, Yamanaka K, Habe K, Morioka T, Kurokawa I, Tsutsui H, Yamanishi K, Nakanishi K, Mizutani H. 2006. Human mast cell chymase cleaves pro-IL-18 and gen- erates a novel and biologically active IL-18 fragment. J Immunol 177:8315-8319.
49. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, et al. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378:88-91.
50. Pauwels RA, Rabe KF. 2004. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 364: 613-620.
51. Peto R, Chen ZM, Boreham J. 1999. Tobacco - the growing epidemic. Nat Med 5:15-17.
52. Pirhonen J, Sareneva T, Julkunen I, Matikainen S. 2001. Virus infection induces proteolytic processing of IL-18 in human macrophages via caspase-1 and caspase-3 activation. Eur J Immunol 31:726-733.
53. Rovina N, Dima E, Gerassimou C, Kollintza A, Gratziou C, Roussos C. 2009. Interleukin-18 in induced sputum: Association with lung function in chronic obstructive pulmonary disease. Respir Med 103:1056-1062.
54. Rowe SJ, Allen L, Ridger VC, Hellewell PG, Whyte MK. 2002. Caspase-1-deficient mice have delayed neutrophil apoptosis and a prolonged inflammatory response to lipopolysaccharide-induced acute lung injury. J Immunol 169:6401-6407.
55. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G, Tropeano G, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM. 1999. CD8+ ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:711-717.
56. Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A, Ciaccia A, Fabbri LM. 1993. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 147:301-306.
57. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. 2008. dentification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17- mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 181:2898-2906.
58. Sims JE. 2002. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 14:117-122.
59. Singh D, Fox SM, Tal-Singer R, Plumb J, Bates S, Broad P, Riley JH, Celli B. 2011. Induced sputum genes associated with spirometric and radiological disease severity in COPD exsmokers. Thorax 66:489-495.
60. Slack J, McMahan CJ, Waugh S, Schooley K, Spriggs MK, Sims JE, Dower SK. 1993. Independent binding of interleukin-1 alpha and interleukin-1 beta to type I and type II interleukin-1 receptors. J Biol Chem 268:2513-2524.
61. Sugawara I, Yamada H, Mizuno S, Takeda K, Akira S. 2003. Mycobacterial infection in MyD88-deficient mice. Microbiol Immunol 47:841-847.
62. Sugawara S, Uehara A, Nochi T, Yamaguchi T, Ueda H, Sugiyama A, Hanzawa K, Kumagai K, Okamura H, Takada H. 2001. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol 167:6568-6575.
63. Takei S, Hoshino T, Matsunaga K, Sakazaki Y, Sawada M, Oda H, Takenaka SI, Imaoka H, Kinoshita T, Honda S, Ida H, Fukuda TA, Aizawa H. 2011. Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. Arthritis Res Ther 13:R52.
64. Tanaka H, Miyazaki N, Oashi K, Teramoto S, Shiratori M, Hashimoto M, Ohmichi M, Abe S. 2001. IL-18 might reflect disease activity in mild and moderate asthma exacerbation. J Allergy Clin Immunol 107:331-336.
65. Thomas PG, Dash P, Aldridge JR, Jr., Ellebedy AH, Reynolds C, Funk AJ, Martin WJ, Lamkanfi M, Webby RJ, Boyd KL, Doherty PC, Kanneganti TD. 2009. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30:566-575.
66. Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M, Kunikata T, Murakami T, Sanou O, Kojima H, Fujii M, Ohta T, Ikeda M, Ikegami H, Kurimoto M. 1997. Purification and characterization of the human interleukin-18 receptor. J Biol Chem 272:25737-25742.
67. Travis WD, Hunninghake G, King TE, Jr., Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T, Martinez FJ, Nagai S, Midthun DE, Muller NL, Nicholson AG, Raghu G, Selman M, Wells A. 2008. Idiopathic nonspecific interstitial pneumonia: Report of an American Thoracic Society project. Am J Respir Crit Care Med 177:1338-1347.
68. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. 2011. nflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol 32:110-116.
69. van de Veerdonk FL, Stoeckman AK, Wu G, Boeckermann AN, Azam T, Netea MG, Joosten LA, van der Meer JW, Hao R, Kalabokis V, Dinarello CA. 2012. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL- 36 receptor antagonist. Proc Natl Acad Sci U S A 109:3001-3005.
70. Visscher DW, Myers JL. 2006. Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc 3:322-329.
71. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. 2006. Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity 24:677-688.
72. Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS, Lam CW. 2001. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol 125:177-183.
73. Wu H, Romieu I, Shi M, Hancock DB, Li H, Sienra-Monge JJ, Chiu GY, Xu H, del Rio-Navarro BE, London SJ. 2010. Evaluation of candidate genes in a genome-wide association study of childhood asthma in Mexicans. J Allergy Clin Immunol 125:321-327. e13.
74. Zheng T, Liu W, Oh SY, Zhu Z, Hu B, Homer RJ, Cohn L, Grusby MJ, Elias JA. 2008. IL-13 receptor alpha2 selectively inhibits IL-13-induced responses in the murine lung. J Immunol 180:522-529.
75. Zhu G, Whyte MK, Vestbo J, Carlsen K, Carlsen KH, Lenney W, Silverman M, Helms P, Pillai SG. 2008. Interleukin 18 receptor 1 gene polymorphisms are associated with asthma. Eur J Hum Genet 16:1083-1090.
76. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 103:779-788.
77. Al-Sadi R, Boivin M, Ma T. 2009. Mechanism of cytokine modulation of epithelial tight junction barrier. Front Biosci 14:2765-2778.
78. Al-Sadi R, Ye D, Dokladny K, Ma TY. 2008. Mechanism of IL- 1beta-induced increase in intestinal epithelial tight junction permeability. J Immunol 180:5653-5661.
79. Al-Sadi R, Khatib K, Guo S, et al. 2011. Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 300: G1054-G1064.
80. Al-Sadi RM, Ma TY. 2007. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol 178: 4641-4649.
81. Atreya I, Atreya R, Neurath MF. 2008. NF-kappaB in inflammatory bowel disease. J Intern Med 263:591-596.
82. Blair SA, Kane SV, Clayburgh DR, Turner Jr. 2006. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest 86:191-201.
83. Chichlowski M, Westwood GS, Abraham SN, Hale LP. 2010. Role of mast cells in inflammatory bowel disease and inflammation- associated colorectal neoplasia in IL-10-deficient mice. PLoS One 5:e12220.
84. Clayburgh DR, Barrett TA, Tang Y, et al. 2005. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest 115:2702- 2715.
85. Cominelli F, Pizarro TT. 1996. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment Pharmacol Ther 10 Suppl 2:49-53; discussion 54.
86. Dijkstra G, Moshage H, Jansen PL. 2002. Blockade of NF-kappaB activation and donation of nitric oxide: New treatment options in inflammatory bowel disease? Scand J Gastroenterol Suppl 236:37-41.
87. Dinarello CA. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095-2147.
88. Dunne A, O'Neill LA. 2003. The interleukin-1 receptor/Toll-like receptor superfamily: Signal transduction during inflammation and host defense. Sci STKE 2003:re3.
89. Ferretti M, Casini-RaggiV, Pizarro TT, et al. 1994. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 94:449-453.
90. Fink MP. 2003. Intestinal epithelial hyperpermeability: Update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care 9:143-151.
91. Graham WV, Wang F, Clayburgh DR, et al. 2006. Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events. Characterization of the human long myosin light chain kinase promoter. J Biol Chem 281:26205-26215.
92. Heresbach D, Alizadeh M, Dabadie A, et al. 1997. Significance of interleukin-1beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am J Gastroenterol 92:1164-1169.
93. Hogan SP, Seidu L, Blanchard C, et al. 2006. Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. J Allergy Clin Immunol 118:257-268.
94. Hollander D, Vadheim CM, Brettholz E, et al. 1986. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 105:883-885.
95. Hollander D. 1988. Crohn's disease - a permeability disorder of the tight junction? Gut 29:1621-1624.
96. Hyams JS, Fitzgerald JE, Wyzga N, et al. 1995. Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease. J Pediatr Gastroenterol Nutr 21: 419-425.
97. Ma T.Y., Anderson JM., Tight junctions and the intestinal barrier. Physiology of the gastrointestinal tract. In 2. 4th ed. Burlington, MA: Elsevier Academic Press. 2006.
98. Ma TY, Anderson JM. 2006 Tight junctions and the intestinal barrier. In: Physiology of the gastrointestinal tract. Vol 2. 4th ed. Burlington, MA: Elsevier Academic Press. Miehsler W, Puspok A, Oberhuber T, Vogelsang H. 2001. Impact of different therapeutic regimens on the outcome of patients with Crohn's disease of the upper gastrointestinal tract. Inflamm Bowel Dis 7:99-105.
99. Nemetz A, Nosti-Escanilla MP, Molnar T, et al. 1999. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 49:527-531.
100. Neurath MF, Fuss I, Schurmann G, et al. 1998. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci 859:149- 159.
101. O'Neill LA, Dinarello CA. 2000. The IL-1 receptor/toll-like receptor superfamily: Crucial receptors for inflammation and host defense. Immunol Today 21:206-209.
102. Poritz LS, Garver KI, Green C, et al. 2007. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res 140:12-19.
103. Reinecker HC, Steffen M, Doehn C, et al. 1991. Proinflammatory cytokines in intestinal mucosa. Immunol Res 10:247-248.
104. Rogler G, Brand K, Vogl D, et al. 1998. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115:357-369.
105. Schwarz BT, Wang F, Shen L, et al. 2007. LIGHT signals directly to intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms. Gastroenterology 132: 2383-2394.
106. Su L, Shen L, Clayburgh DR, et al. 2009. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 136:551-563.
107. Sydora BC, Tavernini MM, Doyle JS, Fedorak RN. 2005. Association with selected bacteria does not cause enterocolitis in IL-10 gene-deficient mice despite a systemic immune response. Dig Dis Sci 50:905-913.
108. Turner JR, Angle JM, Black ED, et al. 1999. PKC-dependent regulation of transepithelial resistance: Roles of MLC and MLC kinase. Am J Physiol 277:C554-C562.
109. Turner JR, Rill BK, Carlson SL, et al. 1997. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol 273:C1378-C1385.
110. Vavricka SR, Rogler G. 2009. New insights into the pathogenesis of Crohn's disease: Are they relevant for therapeutic options? Swiss Med Wkly 139:527-534.
111. Vindenes HA, Ulvestad E, Bjerknes R. 1998. Concentrations of cytokines in plasma of patients with large burns: Their relation to time after injury, burn size, inflammatory variables, infection, and outcome. Eur J Surg 164:647-656.
112. Weber CR, Raleigh DR, Su L, et al. 2010. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem 285:12037-12046.
113. Wyatt J, Vogelsang H, Hubl W, et al. 1993. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 341:1437-1439.
114. Ye D, Guo S, Al-Sadi R, Ma TY. 2011. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology 141:1323-1333.
115. Ye D, Ma TY. 2008. Cellular and molecular mechanisms that mediate basal and tumour necrosis factor-alpha-induced regulation of myosin light chain kinase gene activity. J Cell Mol Med 12:1331-1346.
116. Yoshida H, Russell J, Senchenkova EY, et al. 2010. Interleukin- 1beta mediates the extra-intestinal thrombosis associated with experimental colitis. Am J Pathol 177:2774-2781.
117. Zakostelska Z, Kverka M, Klimesova K, et al. 2011. Lysate of probiotic lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One 6:e27961.